Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as volatility rises quickly?
Biotech Rally Coming In Weeks Ahead? Large cap biopharma and MedTech stocks are leading the healthcare sector higher.
Major Sector ETFs Wildcard: Biotechnology On the weekly chart, IBB is breaking under the 200-week moving average.
Semiconductors Fail A Key Support Level - And More It has been 2 years and 2 months since the ETF for Semiconductors SMH has traded below the 50-week moving average.
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.
4 Sectors That Thrive When Inflation Runs Hot Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value
The Inside Sectors Of The Economy Flash Warning Zooming out to the weekly chart of TLT, we see a double bottom in play from the lows in October 2023 and January 2025.
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.
Biotech Stocks Had A Good Week Despite Crosscurrents It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds.
Do The Major Sector ETFs Love High Flying Stocks? The major sector ETFs remain muted. Nothing screams wildly bullish or horribly bearish in the weekly charts.
Price Action Disputes Most Macro Narratives Do you believe the economy is heading towards inflation? What about a recession? Are gold prices sending a warning? Read on for the answer.
Can Biotech Stocks Survive The Precarious Macro? We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.
Compare/Contrast - Year Of The Yin Wood Snake 1965 And 2025 The Federal debt in 1965 was $322.3 billion. In 2025 it is at $36.24 trillion. The unemployment rate was 5.2%. Now it is at 4.1%.
Small- To Mid-Cap Biotech Trades Poised For Gains On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.
DeepSeek Is Not New - The Rotation Away From Tech Is The technical aspect of DeepSeek is not new. The reaction to it though, is new.
Healthcare And Biotech Stocks Lag The Market Again Biotech stocks got little help from the JPM Conference despite some recovery to the general market.
There May Still Be Time to Get in on These 3 Trending Biotechs Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Major Sector ETFs January Trend Trade is Here Transportation IYT chart is incredible. The price action Friday showed the attempt to take out the January trend trade range and then failed.
Inflation, Soft Landing, January Trend Trade Working Out Sugar, as shown in the weekly chart, has broken down under the 200-WMA for the first time since December 2020. However, it is holding the August 2024 low.
The Major Sector ETFs Remain Technically Intact As long as XRT holds 78.00, it’s back where it broke out from after a massive consolidation last year.
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.
